129 related articles for article (PubMed ID: 38325328)
1. A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma.
Yu S; Yu M; Keane B; Mauro DM; Helft PR; Harris WP; Sanoff HK; Johnson MS; O'Neil B; McRee AJ; Somasundaram A
Oncologist; 2024 Mar; 29(3):270-e413. PubMed ID: 38325328
[TBL] [Abstract][Full Text] [Related]
2. A Phase I/IIa Trial of Yttrium-90 Radioembolization in Combination with Durvalumab for Locally Advanced Unresectable Hepatocellular Carcinoma.
Lee YB; Nam JY; Cho EJ; Lee JH; Yu SJ; Kim HC; Paeng JC; Yoon JH; Kim YJ
Clin Cancer Res; 2023 Sep; 29(18):3650-3658. PubMed ID: 37459133
[TBL] [Abstract][Full Text] [Related]
3. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma.
Salem R; Gordon AC; Mouli S; Hickey R; Kallini J; Gabr A; Mulcahy MF; Baker T; Abecassis M; Miller FH; Yaghmai V; Sato K; Desai K; Thornburg B; Benson AB; Rademaker A; Ganger D; Kulik L; Lewandowski RJ
Gastroenterology; 2016 Dec; 151(6):1155-1163.e2. PubMed ID: 27575820
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcome analysis of Y90 radioembolization in hepatocellular carcinoma.
Lee HM; Alder L; Nguyen M; Dougherty SC; Qu Y; Thacker LR; Poklepovic A
J Gastrointest Oncol; 2023 Jun; 14(3):1378-1391. PubMed ID: 37435218
[TBL] [Abstract][Full Text] [Related]
5. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study.
Kolligs F; Arnold D; Golfieri R; Pech M; Peynircioglu B; Pfammatter T; Ronot M; Sangro B; Schaefer N; Maleux G; Munneke G; Pereira H; Zeka B; de Jong N; Helmberger T;
JHEP Rep; 2023 Feb; 5(2):100633. PubMed ID: 36593888
[TBL] [Abstract][Full Text] [Related]
6. Large, multifocal or portal vein-invading hepatocellular carcinoma (HCC) downstaged by Y90 using personalized dosimetry: safety, pathological results and outcomes after surgery.
Meerun MA; Allimant C; Rivière B; Herrero A; Panaro F; Assenat E; Cassinotto C; Mariano-Goulart D; Guiu B
Hepatobiliary Surg Nutr; 2023 Jun; 12(3):351-365. PubMed ID: 37351147
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of radioembolization with glass microspheres in hepatocellular carcinoma patients with elevated lung shunt fraction: analysis of a 103-patient cohort.
Das A; Riaz A; Gabr A; Ali R; Mora R; Al Asadi A; Mouli S; Lewandowski RJ; Salem R
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):807-815. PubMed ID: 31502015
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection.
Ali R; Riaz A; Gabr A; Abouchaleh N; Mora R; Al Asadi A; Caicedo JC; Abecassis M; Katariya N; Maddur H; Kulik L; Lewandowski RJ; Salem R
Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2195-2202. PubMed ID: 28812136
[TBL] [Abstract][Full Text] [Related]
9. Radioembolization plus Immune Checkpoint Inhibitor Therapy Compared with Radioembolization plus Tyrosine Kinase Inhibitor Therapy for the Treatment of Hepatocellular Carcinoma.
Garcia-Reyes K; Gottlieb RA; Menon KM; Bishay V; Patel R; Patel R; Nowakowski S; Sung MW; Marron TU; Gansa WH; Zhang J; Raja SC; Shilo D; Fischman A; Lookstein R; Kim E
J Vasc Interv Radiol; 2024 May; 35(5):722-730.e1. PubMed ID: 38342221
[TBL] [Abstract][Full Text] [Related]
10. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
Spreafico C; Sposito C; Vaiani M; Cascella T; Bhoori S; Morosi C; Lanocita R; Romito R; Chiesa C; Maccauro M; Marchianò A; Mazzaferro V
J Hepatol; 2018 Apr; 68(4):724-732. PubMed ID: 29331342
[TBL] [Abstract][Full Text] [Related]
11. Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization.
Xing M; Kokabi N; Camacho JC; Kim HS
BMC Cancer; 2018 Jan; 18(1):75. PubMed ID: 29329568
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial.
Verset G; Borbath I; Karwal M; Verslype C; Van Vlierberghe H; Kardosh A; Zagonel V; Stal P; Sarker D; Palmer DH; Vogel A; Edeline J; Cattan S; Kudo M; Cheng AL; Ogasawara S; Daniele B; Chan SL; Knox JJ; Qin S; Siegel AB; Chisamore M; Hatogai K; Wang A; Finn RS; Zhu AX
Clin Cancer Res; 2022 Jun; 28(12):2547-2554. PubMed ID: 35421228
[TBL] [Abstract][Full Text] [Related]
13. Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial.
Chauhan N; Bukovcan J; Boucher E; Cosgrove D; Edeline J; Hamilton B; Kulik L; Master F; Salem R
JMIR Res Protoc; 2018 Aug; 7(8):e11234. PubMed ID: 30111528
[TBL] [Abstract][Full Text] [Related]
14. History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma.
Saini A; Wallace A; Alzubaidi S; Knuttinen MG; Naidu S; Sheth R; Albadawi H; Oklu R
J Clin Med; 2019 Jan; 8(1):. PubMed ID: 30621040
[TBL] [Abstract][Full Text] [Related]
15. Transarterial radioembolization with yttrium-90 of unresectable primary hepatic malignancy in children.
Aguado A; Ristagno R; Towbin AJ; Gupta A; Haberle S; Qi Z; Patel MN; Kukreja KU; Tiao GM; Geller JI
Pediatr Blood Cancer; 2019 Jul; 66(7):e27510. PubMed ID: 30406959
[TBL] [Abstract][Full Text] [Related]
16. Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma.
Gordon AC; Gabr A; Riaz A; Uddin OM; Abouchaleh N; Ali R; Kallini J; Salem R; Lewandowski RJ
Cardiovasc Intervent Radiol; 2018 Oct; 41(10):1557-1565. PubMed ID: 29948005
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Overall and Progression-Free Survival in Patients with Ocular Melanoma Metastatic to the Liver Undergoing Y90 Radioembolization.
Levey AO; Elsayed M; Lawson DH; Ermentrout RM; Kudchadkar RR; Bercu ZL; Yushak ML; Newsome J; Kokabi N
Cardiovasc Intervent Radiol; 2020 Feb; 43(2):254-263. PubMed ID: 31686137
[TBL] [Abstract][Full Text] [Related]
18. Yttrium-90 Radioembolization Therapy for Combined Hepatocellular and Cholangiocarcinoma.
Badar W; Van Ha T; Zangan S; Navuluri R; Pillai A; Baker T; Ahmed O
Gastrointest Tumors; 2020 Oct; 7(4):144-150. PubMed ID: 33173778
[TBL] [Abstract][Full Text] [Related]
19. Study Protocol: Efficacy and Safety of Radioembolization (REM) as an Early Modality (EM) Therapy for Metastatic Breast Cancer (BR) to the Liver with Y90 (REMEMBR Y90).
Wu R; Gogineni K; Meisel J; Szabo S; Thirunavu M; Friend S; Bercu Z; Sethi I; Natarajan N; Switchenko J; Levy J; Abdalla E; Weakland L; Kalinsky K; Kokabi N
Cardiovasc Intervent Radiol; 2022 Nov; 45(11):1725-1734. PubMed ID: 36008574
[TBL] [Abstract][Full Text] [Related]
20. Unresectable Intrahepatic Cholangiocarcinoma Treated with Radiation Segmentectomy/Lobectomy Using Yttrium 90-labeled Glass Microspheres.
Kumar P; Mhaskar R; Kim R; Anaya D; Frakes J; Hoffe S; Choi J; Kis B
J Clin Exp Hepatol; 2022; 12(5):1259-1263. PubMed ID: 36157145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
